Nasdaq
$0.3948▲ 0.97%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $708,768.65Shares out 1.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 10.13Regular26.10.13 23:0725-NSEOther#●●●#●●●#●●●
Bone Biologics CorpBullish
Bone Biologics Corp has received a delist determination from Nasdaq. Consequently, trading of the company's securities will be suspended before the market opens on May 22, 2024, and the delisting is finalized.…more
$0.3948+0.97%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30After-hours26.10.01 06:144Ownership
Bone Biologics Corp
Bone Biologics Corp insider Robert E. Gagnon filed a Form 4 on September 30, 2026, reporting a change in beneficial ownership of securities as of September 28, 2026. This filing formalizes the recent equity transaction by the executive.…more
$0.3948+0.97%vs prev closeView filingShare - 9.30After-hours26.10.01 06:124Ownership
Bone Biologics Corp
Insider Siddhesh Rajendra Angle of Bone Biologics Corp filed a Form 4 statement regarding changes in beneficial ownership of securities as of September 28, 2026. This filing serves as an official record of the insider's equity transaction.…more
$0.3948+0.97%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.8Pre-market26.09.08 21:30#●●●#●●●#●●●
Bone Biologics Expands Clinical Trial Sites for NB1
Bone Biologics has doubled its clinical trial sites in Australia to six, aiming to complete patient enrollment by the end of 2026. While this expansion is intended to accelerate the pilot study, the company remains in the early stages of clinical development.…more
$0.3948+0.97%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.8Pre-market26.09.08 21:32
●●●●●●●● ●●●●● ●●●●●●
Bone Biologics has secured agreements with six Australian hospitals for its first-in-human NB1 spinal fusion pilot trial, doubling the number of participating centers. The company expects to complete patient enrollment by the end of 2026.…more
$0.3948+0.97%vs prev closeShareBenzinga - 9.3Pre-market26.09.03 21:30
●●●●●●●● ●●●●● ●●●●●●
Bone Biologics announced its participation in the upcoming H.C. Wainwright 28th Annual Global Investment Conference to engage with investors. The event will feature one-on-one meetings and a virtual presentation, though no specific financial or operational milestones were disclosed.…more
$0.3948+0.97%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report